UCB adds on more positive PhIII data for IL-17A/17F inhibitor bimekizumab, clearing a path to the FDA

UCB adds on more positive PhIII data for IL-17A/17F inhibitor bimekizumab, clearing a path to the FDA

Source: 
Endpoints
snippet: 

A month after posting positive top-line data from their first Phase III trial of the IL-17A/17F inhibitor bimekizumab, Belgium’s UCB says they’ve added more upbeat results from their second late-stage test in moderate-to-severe plaque psoriasis.